CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients - PubMed (original) (raw)
. 2011 May;121(5):1822-6.
doi: 10.1172/JCI46110. Epub 2011 Apr 11.
Carlos Almeida Ramos, Enli Liu, Martha P Mims, Michael J Keating, George Carrum, Rammurti T Kamble, Catherine M Bollard, Adrian P Gee, Zhuyong Mei, Hao Liu, Bambi Grilley, Cliona M Rooney, Helen E Heslop, Malcolm K Brenner, Gianpietro Dotti
Affiliations
- PMID: 21540550
- PMCID: PMC3083795
- DOI: 10.1172/JCI46110
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al. J Clin Invest. 2011 May.
Abstract
Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were simultaneously infused with 2 autologous T cell products expressing CARs with the same specificity for the CD19 antigen, present on most B cell malignancies. One CAR encoded both the costimulatory CD28 and the ζ-endodomains, while the other encoded only the ζ-endodomain. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced expansion and persistence compared with CAR+ T cells lacking this endodomain. These results demonstrate the superiority of CARs with dual signal domains and confirm a method of comparing CAR-modified T cells within individual patients, thereby avoiding patient-to-patient variability and accelerating the development of optimal T cell immunotherapies.
Figures
Figure 1. Transduction efficiency and phenotypic/function profile of T cell lines.
(A) FACS and Q-PCR analyses showing transduction efficiency with CAR.CD19ζ and CAR.CD19-28ζ vectors (left). Bars indicate mean values for peripheral blood samples from 6 patients (Supplemental Table 1). Each symbol represents an individual cell line. Representative histograms of T cells transduced with CAR.CD19ζ and CAR.CD19-28ζ vectors from patients number 1 and number 5 are also presented (right). Numbers represent the percentage of CAR+ cells. (B) Results of a 4-hour 51Cr-release assay at an effector/tumor cell (E/T) ratio of 20:1. Target cells were Raji (CD19+, CD80+, CD86–), a Burkitt lymphoma cell line; HLDM-2 (CD19–, CD80+, CD86+), a Hodgkin lymphoma cell line; and K562 (CD19–, CD80–, CD86–), an erythroid leukemia cell line that is susceptible to natural killer cell activity. Both CAR.CD19ζ+ and CAR.CD19-28ζ+ T cells specifically targeted CD19+ tumors. Data are mean ± SD for the 6 T cell lines. (C) Phenotypic composition of CAR.CD19ζ+ or CAR.CD19-28ζ+ T cells. These products contained both CD8+ and CD4+ CAR-expressing T cells that are predominantly CD45RO+CD62L+, with a fraction of them expressing CD28. Each symbol represents an individual cell line, and horizontal bars denote mean group values.
Figure 2. In vivo expansion and persistence of infused CAR.CD19ζ+ versus CAR.CD19-28ζ+ T cell lines as assessed by Q-PCR in peripheral blood.
Data points represent critical postinfusion intervals after the first or second infusion of modified T cells. Patients number 1, number 3, and number 5, who had stable disease or clinical benefit at 6 weeks after the first T cell infusion, received a second infusion of CAR-modified T lymphocytes. Patient number 1 received only CAR.CD19-28ζ+ T cells (2 × 107 cells/m2, the same as for the first infusion), because this was the only product available. Patient number 3 received both CAR.CD19-28ζ+ and CAR.CD19ζ+ T cells, but the cell dose was 60% of their first dose (1 × 108 cells/m2). Patient number 5 received both CAR.CD19-28ζ+ and CAR.CD19ζ+ T cells at the same dose administered during their first infusion (2 × 108 cells/m2). Open arrows indicate the time of T cell infusion, and dashed arrows indicate the time when chemotherapy was initiated for disease progression. Pre, before the first infusion; Pre II, before the second infusion.
Figure 3. Detection of CAR+ T cells in a skin tumor biopsy.
(A) Immunohistochemical examination (diaminobenzidine with hematoxylin counterstaining) of a punch biopsy of a lymphoma skin lesion from patient number 5 at 2 weeks after T cell infusion showed that tumor cells were CD20+ (shown), CD10+, BCL2+, and BCL6+, consistent with involvement by follicular lymphoma with large cell transformation. Scattered CD3+ CD8+ cells infiltrated the tumor. Of note, the infused CAR.CD19-28ζ+ product consisted of 85% CD8+ cells. Scale bar: 100 μm. (B) FACS analysis of a cell suspension obtained from a fragment of the tumor biopsy. Viable cells represented approximately 45% of the preparation. The far left panel shows the gate on CD45+ cells, which represented 12% of the viable cells. The middle panel shows the CD3+ lymphocytes infiltrating the tumor, which accounted for 6.7% of CD45+ cells (0.8% of all viable cells). The far right panel illustrates that 20% of the gated CD3+ lymphocytes cells coexpressed the CAR, as assessed by the Fc-Cy5 monoclonal antibody, which binds to the IgG1-CH2CH3 spacer region of the CD19-specific CARs (~0.16% of all viable cells). SSC, side scatter.
Comment in
- Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients.
Gandhi M, Jones K. Gandhi M, et al. Immunotherapy. 2011 Dec;3(12):1441-3. doi: 10.2217/imt.11.135. Immunotherapy. 2011. PMID: 22091680
Similar articles
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ. Wang X, et al. Blood. 2016 Jun 16;127(24):2980-90. doi: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26. Blood. 2016. PMID: 27118452 Free PMC article. Clinical Trial. - In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z, Wei R, Ma Q, Shi L, He F, Shi Z, Jin T, Xie R, Wei B, Chen J, Fang H, Han X, Rohrs JA, Bryson P, Liu Y, Li QJ, Zhu B, Wang P. Cheng Z, et al. Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2. Mol Ther. 2018. PMID: 29503204 Free PMC article. Clinical Trial. - In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G. Ramos CA, et al. Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13. Mol Ther. 2018. PMID: 30309819 Free PMC article. - Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality.
Smith R, Shen R. Smith R, et al. J Transl Med. 2023 Jul 30;21(1):515. doi: 10.1186/s12967-023-04372-4. J Transl Med. 2023. PMID: 37518011 Free PMC article. Review. - A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.
Cappell KM, Kochenderfer JN. Cappell KM, et al. Nat Rev Clin Oncol. 2021 Nov;18(11):715-727. doi: 10.1038/s41571-021-00530-z. Epub 2021 Jul 6. Nat Rev Clin Oncol. 2021. PMID: 34230645 Review.
Cited by
- The first century of JCI and beyond.
McNally EM. McNally EM. J Clin Invest. 2024 Oct 1;134(19):e186113. doi: 10.1172/JCI186113. J Clin Invest. 2024. PMID: 39352384 Free PMC article. No abstract available. - The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management.
Anurogo D, Luthfiana D, Anripa N, Fauziah AI, Soleha M, Rahmah L, Ratnawati H, Wargasetia TL, Pratiwi SE, Siregar RN, Sholichah RN, Maulana MS, Ikrar T, Chang YH, Qiu JT. Anurogo D, et al. Adv Pharm Bull. 2024 Jul;14(2):314-330. doi: 10.34172/apb.2024.034. Epub 2024 Mar 10. Adv Pharm Bull. 2024. PMID: 39206402 Free PMC article. Review. - Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder.
Mai Q, He B, Deng S, Zeng Q, Xu Y, Wang C, Pang Y, Zhang S, Li J, Zeng J, Huang L, Fu Y, Li C, Li T, Xu X, Zhang L. Mai Q, et al. Exp Hematol Oncol. 2024 Aug 19;13(1):85. doi: 10.1186/s40164-024-00553-z. Exp Hematol Oncol. 2024. PMID: 39160631 Free PMC article. - The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas.
Haydu JE, Abramson JS. Haydu JE, et al. Blood Adv. 2024 Sep 10;8(17):4700-4710. doi: 10.1182/bloodadvances.2021004535. Blood Adv. 2024. PMID: 39042891 Free PMC article. Review. - Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo.
He H, Vedia RA, Lu S, Li Q, Cox KR, St John L, Sergeeva A, Clise-Dwyer K, Alatrash G, Shpall EJ, Ma Q, Molldrem JJ. He H, et al. Cytotherapy. 2024 Nov;26(11):1331-1340. doi: 10.1016/j.jcyt.2024.06.010. Epub 2024 Jul 3. Cytotherapy. 2024. PMID: 39033444
References
- Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–724. doi: 10.1073/pnas.90.2.720. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 CA126752/CA/NCI NIH HHS/United States
- P30 CA125123/CA/NCI NIH HHS/United States
- 3P50CA126752/CA/NCI NIH HHS/United States
- P01 CA094237/CA/NCI NIH HHS/United States
- P50 CA126752-03/CA/NCI NIH HHS/United States
- P01 CA094237-09/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical